



July 2011

Highlights from ASCO 2011: TRM Network Investigator Michael Gordon, M.D.

Michael Gordon, MD, President and CEO of Pinnacle Oncology in Scottsdale, Arizona, was featured from among more than 4,000 abstracts and presented results of a Phase II study of Cabozantinib (XL184) in solid tumors. Cabozantinib is an oral inhibitor of MET and VEGFR2 kinases and showed strong responses in a variety of advanced cancers. Results were particularly strong for patients with advanced prostate, ovarian and liver cancers (which have been historically resistant to available therapies) and fully or partially eliminated bone metastases in patients with breast and prostate cancers and melanoma. The article [MET, VEGFR2 Inhibition Appears Beneficial in Advanced Solid Tumors](#) appeared in the ASCO Daily News as well as various other media outlets including the ASCO Post.

[Back to top](#)

STUDY SPOTLIGHT

Farletuzumab in Combination with Carboplatin and Paclitaxel or Docetaxel followed by Pemetrexed in Patients with Adenocarcinoma of the Lung with Wild Type EGFR - Open and Accruing

The study, sponsored by Morphotek Inc., is now actively enrolling patients at TRM locations in Arizona, Los Angeles and Central California. Key inclusion criteria for this study are as follows:

- * Histologically or cytologically confirmed adenocarcinoma of the lung classified as stage IV
- * Confirmed folate receptor-alpha (FRA) expression by IHC
- * Measurable disease with at least one unidimensionally measurable lesion according to RECIST criteria version 1.1 by CT or MRI scans (CT or MRI scans must have been performed within 30 days prior to the first dose of farletuzumab or placebo)
- * Must have received no prior chemotherapy, radiation therapy or surgery with curative intent for adenocarcinoma of the lung

NEWS

INDUSTRY NEWS

MD Anderson Cancer Center study reports many advanced breast cancer patients do not receive recommended treatment

Radiation after a mastectomy for women with advanced breast cancer saves lives, but almost half of these patients do not receive it. That is the conclusion of a new study published early online in *CANCER*, a peer-reviewed journal of the American Cancer Society. The study's results indicate that treatments that have proven their life-saving potential in clinical trials may not be available to many patients. For the full news release, go to www.mdanderson.org.

Stand Up To Cancer Co-Founder Laura Ziskin Dies at Age 61

Acclaimed film producer and cancer activist Laura Ziskin died June 12, 2011, at the age of 61. Ziskin, who lived with breast cancer for seven years, was executive producer of two [Stand Up To Cancer](#) telecasts in 2008 and 2010. The telecasts aired on three broadcast networks and cable channels featuring various public figures and celebrities and raised \$180 million dollars to support innovative cancer researchers across the world.

DID YOU KNOW

TRM conducts monthly research training modules on Good Clinical Practice, Ethical Standards for Research Involving Human Subjects

For more information on this study or any other TRM managed clinical trial, please [contact TRM](#) or visit the Study Information page on our website, www.trmlc.com.

[Back to top](#)

SITE SPOTLIGHT

Southern California Oncology Associates

TRM is pleased to announce the latest partner to join our growing network of oncologists: [Southern California Oncology Associates \(SCOA\)](#). This affiliated group of 11 oncology practices in Southern California will be conducting clinical trials at a number of their key locations and incorporating clinical trial participation into their continuum of care. SCOA brings 30 forward-thinking physicians to the TRM network with the commitment to participate in research. We are looking forward to our future collaborations.

[Back to top](#)

Now Hiring

Due to continued growth and expansion, TRM is seeking qualified candidates for our Site Relationship Manager (SRM) position(s). SRM's are responsible for managing all clinical trial deliverables to completion for assigned TRM Network sites and act as the primary contact for ongoing site problem resolution. Qualified candidates must have had experience working within oncology clinical trials. Please contact us directly by phone at 424-208-8866 or email resumes@trmlc.com if you or someone you may know would be interested in joining our dynamic team.

[Back to top](#)

TRM and the TRM Logo are registered trademarks of [Translational Research Management](#).
Translational Research Management - 11755 Wilshire Blvd Suite 2310, Los Angeles, CA 90025.
ph 424-208-8866 - fax 424-208-8877

and Guidelines for Shipping of Biological Materials for all TRM network site investigators and staff members that have not had the training or have not had their training renewed in the last two years.

The next regularly scheduled training will take place on Friday, July 22nd. Please contact your SRM for details on how to participate.

Unsubscribe

Click to instantly unsubscribe from this mailing list.

Send to a friend

Send this email to someone you think may be interested.